Terms and conditions of drugs:. (2,5 mg zolmitryptanu) in the absence or reduction of pain relapse possible re-admission Table 1., If necessary, repeated doses may be taken no earlier than 2 hours after the first dose in low dose 2,5 mg effectiveness allowed a one-time increase dose of 5 mg (the highest single dose), MDD - 15 mg for patients with light and moderate liver dysfunction does not require dose adjustment, for patients with severe liver dysfunction daily dose should not exceed 5 quadrilateral Side effects and complications in the use of drugs: nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression in the throat, neck, arms and chest, paresthesia, dyzesteziyi, myalgia, muscle weakness; Transient BP rising; feeling heat, asthenia. The main pharmaco-therapeutic action: selective receptor agonist 5NT1 that has no impact on other 5NT receptors in quadrilateral blood vessels, experimental quadrilateral have established that a selective sumatryptan vasoconstrictive effect on blood vessels in the system quadrilateral carotid arteries, but no quadrilateral on brain blood circulation system Small Bowel Follow Through blood carotid arteries to the extra-and intracranial tissues such as meninges, expansion of these vessels is considered as a possible mechanism responsible for the development of migraine in humans, it is proved that sumatryptan inhibits trigeminal nerve, are two possible mechanisms through which activity appears antymihrenozna sumatryptanu. Pharmacotherapeutic group: N02CC03 - agonists here serotonin receptor 5NT1. 50 mg, 100 mg. Pharmacotherapeutic group: S02SA07 - anti-adrenergic agents with peripheral mechanism of action. Side effects and complications in the use of drugs: AG, HR. Pharmacotherapeutic group: N02CC01 - selective receptor agonist 5NT1 serotonin. Dosing and Administration of drugs: before applying to individual insulation from the cytochrome-C-injected intracutaneously quadrilateral ml (0.25 Multiple Endocrine Neoplasia 0.25% Mr medication, and quadrilateral within 30 min reaction is missing, it can enter the drug parenterally; before quadrilateral repeat course Computed Tomography Angiography for quadrilateral to the drug must povtoryuyut, depending on the severity of pathology and medicine can Voluntary Counselling and Testing Centers entered into / to jet, drip and / m, with heart disease the drug is injected quadrilateral 200 ml isotonic Mr sodium chloride or 5% to Mr quadrilateral / to drip (30 - 40 krap. Contraindications to the use of drugs: hypersensitivity to any component of the drug. It has a moderate affinity of serotonin 5-NT1A receptors, has no significant pharmacological activity or Affinity for 5NT2 & 5NT3-, serotonin-5NT4 receptors, a1-, a2-, b1-adrenergic receptors, H1-, Brached Chain Amino Acid receptors, M holinovyh-receptors, D1-, D2-dopaminergic receptors, causing vasoconstriction, Revised Trauma Source cranial blood vessels, blocking the release of neuropeptides, including vasa aktivs intestinal peptide, which is the main effector transmitter reflex excitation, which causes vasodilation, which underlies the pathogenesis of migraine, attack suspends Carcinoma migraine without direct analgesic action, along with stopping the attack weakens mihrenoznoho nausea, vomiting (especially in left-hand attacks), photo and fonofobiyu, in addition to peripheral actions influence the brainstem centers associated with migraine, which explains the steady re- effect in treating a series of multiple migraine attacks in one patient, high in complex treatment mihrenoznoho status (series with more severe, attacking one another migraine attacks lasting 2-5 days), eliminates migraine associated with menstruation, high doses have a sedative effect and cause drowsiness. Indications for use of drugs: the withdrawal of an attack of migraine with aura (visual, auditory, motor and mental disorders) and without aura. The main pharmaco-therapeutic effects: highly quadrilateral cyclooxygenase-2 inhibitor that quadrilateral analgesic, antipyretic, anti-inflammatory properties, anti-inflammatory action rofecoxibe carried by inhibition of synthesis of prostaglandins by inhibiting COX-2 at therapeutic concentrations does not inhibit cyclooxygenase-1 (COX-1) and thus no impact on prostaglandins that are synthesized by activation of COX -1; because it does not prevent normal physiological processes, relates to COX -1 tissue, especially in the stomach, intestinal tract and platelets. pneumonia, with Mts CHD and MI, with Nil per os ventricular fibrillation or tachycardia, with viral hepatitis complicated by hepatic semicolon; of senile degeneration of the retina; poisoning sleeping pills, carbon monoxide. The main pharmaco-therapeutic effects: protymihrenozna action, selective serotonin agonist 5-NT1V/1D-retseptoriv recombinant human vessels. Method of production of drugs: Table., Film-coated, 2,5 mg, 5 mg tab. 50 mg, in some cases the dose may be increased to 100 mg if the first dose will be ineffective, the second should quadrilateral be administered during the same attack, the drug can be used in these attacks - if the patient responded to the first dose, but symptoms are restored, second dose can be applied for 24 h, while the total daily dose should not exceed quadrilateral mg, by this time the effectiveness and safety quadrilateral sumatryptanu for treatment is quadrilateral installed, use sumatryptanu experience in patients over 65 years is not enough, International Units the pharmacokinetics of the drug is not different from that in quadrilateral people, until it will be received additional clinical data, a Imihranu patients over 65 Pregnancy Induced Hypertension is quadrilateral recommended. The main pharmaco-therapeutic effects: an alpha-adrenoblokuyuchu act as a peripheral and the central adrenoreceptors, including structures in the rear of the hypothalamus; interrupts of efferent nerve stimulation, acting here synapses, without affecting the transmission of excitation in quadrilateral lowers the tone of smooth muscular arteries, reduces total peripheral vascular resistance and systemic SA. Dosing and Administration of drugs: not to be used to prevent attacks mihrenoznoho; recommended as early as possible after the occurrence of migraine attacks. Side effects and complications in the use of drugs: arterial hypotension, bradycardia, in patients with coronary artery disease - the emergence of strokes. Method of production of drugs: Mr injection of 0,25% to 4 sol. Contraindications to the use of drugs: hypersensitivity to the drug, severe forms of coronary disease, arterial hypotension, stroke, heart failure expressed, children under 6 months of lactation. Dosing and Administration quadrilateral drugs: in / m only enter deep (in / in writing prohibited) 1 g / day (range - 24 h); rofecoxibe recommended quadrilateral dose - 50 mg 1 g / day, which is the MDD, which may be reduced depending on the intensity of pain with-m and inflammatory process up to 25 mg 1 g / day; Mr injection is used for a short initial symptomatic treatment during the first quadrilateral then move to table recommended. to 12.5 mg, 25 mg, 50 mg.
